Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 4Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Leukemia, Myeloid, Acute 52Myelodysplastic Syndromes 25Multiple Myeloma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia 23Lymphoma 22Lymphoma, Non-Hodgkin 21Leukemia, Lymphocytic, Chronic, B-Cell 21Melanoma 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Neoplasms 13Hodgkin Disease 13Neoplasm Metastasis 12Recurrence 11Hematologic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Skin Neoplasms 8Neoplasms, Plasma Cell 8Myeloproliferative Disorders 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Lymphoma, B-Cell 8Kidney Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 7Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Primary Myelofibrosis 5Anemia, Refractory, with Excess of Blasts 5

Interventions

Carboplatin 7Pemetrexed 5pembrolizumab 4Gemcitabine 4osimertinib 3Sorafenib 3Paclitaxel 3Interleukin-2 3Cyclophosphamide 3Cisplatin 3seocalcitol 2selinexor 2patritumab 2liposomal doxorubicin 2interferon gamma-1b 2fludarabine 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Irinotecan 2Erlotinib Hydrochloride 2DNA 2Celecoxib 2Capecitabine 2Bleomycin 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2volociximab 1thioredoxin reductase inhibitor AM12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma × fludarabine × Clear all
NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04596033 2022-07-15

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Genocea Biosciences, Inc.

Phase 1 Terminated
49 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡